[
  {
    "question": "Young female with stroke & recurrent abortion",
    "option_a": "(Protein C deficiency) and option b (Antithrombin III deficiency) predispose mainly to venous thrombosis and do not explain recurrent abortions. Option d (Anti",
    "option_b": "",
    "option_c": ", Antiphospholipid syndrome, best fits the clinical scenario with its dual presentation of arterial stroke and recurrent pregnancy loss.",
    "option_d": "",
    "option_e": "",
    "correct_answer": "c",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "Antiphospholipid syndrome (APS) is an autoimmune disorder marked by the presence of antiphospholipid antibodies (such as lupus anticoagulant, anticardiolipin, and anti-\u03b22 glycoprotein I) that predispose patients to thrombosis. The syndrome uniquely presents with both arterial events (e.g., stroke) and obstetric complications (e.g., recurrent early pregnancy loss). In APS, antibodies target plasma proteins bound to phospholipids, leading to endothelial cell activation, platelet aggregation, and a prothrombotic state. Vascular occlusion in cerebral arteries can lead to stroke, while placental thrombosis causes recurrent miscarriages. Recent studies have further clarified the role of these antibodies in disrupting annexin V shields and promoting coagulation. Young females presenting with neurological deficits such as stroke in combination with a history of recurrent abortions should raise suspicion for APS. The clinical picture is distinct because most inherited thrombophilias, like Protein C or antithrombin III deficiencies, predominantly predispose to venous thrombosis without the obstetric complications seen in APS. The workup involves laboratory testing for lupus anticoagulant, anticardiolipin antibodies, and anti-\u03b22 glycoprotein I on two separate occasions (at least 12 weeks apart). Differential diagnoses include inherited thrombophilias (e.g., Protein C deficiency, antithrombin deficiency) and other autoimmune disorders (secondary APS associated with SLE), but the combined arterial thrombosis and miscarriage history is highly characteristic of APS. First-line management for APS with a history of thrombotic events includes long-term anticoagulation, typically with warfarin (with a target INR of 2-3). In pregnant women, warfarin is contraindicated due to teratogenicity; therefore, treatment involves low molecular weight heparin (LMWH) combined with low-dose aspirin. In non-pregnant patients, direct oral anticoagulants (DOACs) are under investigation, but warfarin remains the standard in high-risk APS. Option a (Protein C deficiency) and option b (Antithrombin III deficiency) predispose mainly to venous thrombosis and do not explain recurrent abortions. Option d (Anti-factor VII antibodies) is not recognized as a cause of hypercoagulability; factor VII deficiency usually leads to bleeding. Option c, Antiphospholipid syndrome, best fits the clinical scenario with its dual presentation of arterial stroke and recurrent pregnancy loss. 1) Always suspect APS in young females with stroke and a history of miscarriage. 2) Confirmatory testing requires repeat antibody assays at least 12 weeks apart. 3) Anticoagulation regimens differ in pregnant patients (LMWH + aspirin) compared to non-pregnant patients (warfarin). Recent guidelines and consensus statements from rheumatology and hematology societies emphasize the importance of early diagnosis and appropriate anticoagulation in APS. While DOACs are emerging, warfarin remains the first-line treatment in high-risk APS patients, and management in pregnancy continues to favor LMWH with low-dose aspirin based on current research.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Middle age male Rt hemiplegia , found to have AF with attached CT brain, ttt",
    "option_a": "(ASA) and option b (dual antiplatelet therapy with ASA & Plavix) have been shown to be inferior to anticoagulation in AF",
    "option_b": "",
    "option_c": ", warfarin, effectively reduces the risk of cardioembolic events and is considered an evidence",
    "option_d": "(LMWH) is not used for long",
    "option_e": "",
    "correct_answer": "c",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "Atrial fibrillation (AF) is a common cardiac arrhythmia that predisposes patients to thrombus formation in the atria, which can embolize to the brain causing ischemic stroke. Effective stroke prevention in AF is achieved by systemic anticoagulation. In AF, the irregular and often rapid atrial contractions lead to stasis of blood, especially in the left atrial appendage, promoting clot formation. These clots can then dislodge and travel to cerebral arteries causing embolic strokes. Anticoagulation with warfarin inhibits the vitamin K-dependent synthesis of clotting factors II, VII, IX, and X, thereby reducing the risk of thrombosis. A middle-aged male presenting with right hemiplegia and a new stroke on CT in the setting of AF fits the classic picture of a cardioembolic stroke. Prevention of future embolic events is critical in such patients. After initial brain imaging (CT scan) confirms ischemic stroke, further cardiac evaluation with echocardiography is standard. When echocardiography is normal and AF is present, the focus shifts to long-term anticoagulation. Differential diagnoses include other causes of stroke such as carotid artery disease or intracranial hemorrhage, but the presence of AF strongly points toward a cardioembolic source. First-line management for stroke prevention in AF typically involves anticoagulation. While direct oral anticoagulants (DOACs) have largely supplanted warfarin in many settings due to ease of use and lower bleeding risks, warfarin remains a standard option particularly when DOACs are contraindicated or unavailable. In pregnant women, warfarin is contraindicated due to teratogenic risks, and LMWH is preferred. In lactating women, warfarin is considered safe but DOACs are generally not recommended. Option a (ASA) and option b (dual antiplatelet therapy with ASA & Plavix) have been shown to be inferior to anticoagulation in AF-related stroke prevention. Option d (LMWH) is not used for long-term outpatient management of AF. Option c, warfarin, effectively reduces the risk of cardioembolic events and is considered an evidence-based choice in appropriate clinical contexts. 1) AF is a high-risk arrhythmia for cardioembolic stroke, necessitating effective anticoagulation therapy. 2) DOACs are increasingly used; however, warfarin remains an acceptable option in many situations. 3) Special considerations are needed for anticoagulation therapy in pregnancy and lactation. While recent guidelines increasingly favor DOACs for non-valvular AF, warfarin remains a cornerstone in stroke prevention for certain patient groups and settings. Clinical trials have demonstrated a significant reduction in stroke risk with proper anticoagulation compared to antiplatelet therapy.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Patient with 3 mm Hemorrhage in putamen, stable hemorrhage but had increased oedema & decrease LOC, ttt",
    "option_a": "(Triple H therapy) is inappropriate as it is used in managing vasospasm in subarachnoid hemorrhage. Option b (Osmotic treatment) may transiently reduce ICP but does not address ongoing mass effect in a deteriorating patient. Option c (Dexamethasone) has been proven ineffective and is potentially harmful in ICH. Option d (Surgical evacuation) is correct as it directly alleviates the mass effect and reduces the risk of further neurological deterioration.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "d",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "Intracerebral hemorrhage (ICH) in the putamen is typically related to hypertensive hemorrhage. Even a small hematoma (e.g., 3 mm) can be surrounded by significant edema, leading to increased intracranial pressure (ICP) and neurological deterioration such as decreased level of consciousness. Following hemorrhage, blood products and clot retraction trigger an inflammatory cascade resulting in vasogenic edema. The expanding edema may cause a mass effect that further compromises adjacent brain structures. Although the hematoma itself is small, the associated swelling can lead to significant clinical deterioration. In this case, despite a stable hemorrhage size, the patient\u2019s declining level of consciousness is clinically significant and suggests worsening mass effect from cerebral edema. This scenario necessitates prompt intervention to reduce ICP and prevent herniation. Serial brain imaging (primarily CT scans) is used to monitor the size of the hemorrhage and associated edema. Differential diagnoses for acute neurological decline in ICH include hematoma expansion, hydrocephalus, or re-bleeding. In this context, the stable hematoma but increased edema indicates that mass effect is the culprit. Initial management includes blood pressure control, reversal of any coagulopathy, and measures to reduce ICP (e.g., osmotic agents like mannitol or hypertonic saline). However, when neurological deterioration occurs due to significant mass effect from edema, surgical evacuation is recommended. Current guidelines advise considering surgical intervention for patients who deteriorate neurologically despite medical management. In a pregnant patient, special consideration would be given to the timing and type of surgery and the anesthetic management, balancing maternal and fetal risks. Option a (Triple H therapy) is inappropriate as it is used in managing vasospasm in subarachnoid hemorrhage. Option b (Osmotic treatment) may transiently reduce ICP but does not address ongoing mass effect in a deteriorating patient. Option c (Dexamethasone) has been proven ineffective and is potentially harmful in ICH. Option d (Surgical evacuation) is correct as it directly alleviates the mass effect and reduces the risk of further neurological deterioration. 1) In ICH, clinical deterioration may result from progressive edema even if the hematoma is small. 2) Surgical intervention is reserved for cases where medical management fails and neurological status worsens. 3) Triple H therapy is specific to cerebral vasospasm in subarachnoid hemorrhage and not applicable in ICH. Recent trials and meta-analyses have shown that while medical management is first-line in many ICH cases, selected patients with deep hemorrhages and evidence of mass effect with clinical decline may benefit from surgical evacuation. Steroid use (such as dexamethasone) has been expressly discouraged based on high-quality evidence demonstrating no benefit and possible harm.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "MRI (DWI) multiple infarctions in one side, NL ECHO- Next step",
    "option_a": "(CTA) is correct because it provides detailed imaging of both extracranial and intracranial arteries and is rapid and widely available. Option b (Doppler ultrasound) is limited by operator dependency and inability to fully image intracranial vessels. Option c (MRA) is less sensitive for detecting calcific plaques and may not be as readily available in acute settings. Thus, CTA stands out as the most appropriate next diagnostic step.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "Multiple acute infarctions on diffusion-weighted imaging (DWI) confined to one side of the brain suggest an embolic phenomenon likely arising from an arterial source rather than a cardiac source, especially when the echocardiogram is normal. The presence of multiple infarcts often implies an artery-to-artery embolism, possibly due to atherosclerotic plaque rupture or dissection. Computed tomography angiography (CTA) provides detailed images of both extracranial and intracranial vessels, identifying stenosis, occlusions, or unstable plaques that may shed microemboli. In a patient with acute ischemic stroke and multiple infarctions on the same side, a normal echocardiogram decreases the likelihood of cardioembolism. Thus, evaluating the arterial system, especially the carotid and vertebral arteries, is crucial to determine the source of emboli. After a normal echocardiogram, the next step is vascular imaging. Differential diagnoses include carotid artery stenosis, arterial dissection, and intracranial atherosclerotic disease. While Doppler ultrasound is useful as a screening tool, it is operator dependent and less sensitive for intracranial pathology. Magnetic resonance angiography (MRA) is an alternative but may not detect calcified plaques as reliably as CTA. The current guidelines recommend CTA as the next diagnostic step for rapid and comprehensive evaluation of the cerebrovascular tree. Following identification of the underlying pathology, management may include antiplatelet therapy, statins, and risk factor modification. In pregnant patients, radiation exposure from CTA is a concern; in such cases, magnetic resonance angiography (MRA) may be considered as an alternative. During lactation, the risk is much lower, and CTA can generally be performed with proper safety measures. Option a (CTA) is correct because it provides detailed imaging of both extracranial and intracranial arteries and is rapid and widely available. Option b (Doppler ultrasound) is limited by operator dependency and inability to fully image intracranial vessels. Option c (MRA) is less sensitive for detecting calcific plaques and may not be as readily available in acute settings. Thus, CTA stands out as the most appropriate next diagnostic step. 1) In stroke workup with multiple infarcts and a normal echocardiogram, always consider an arterial source such as carotid stenosis or plaque rupture. 2) CTA is the gold standard for quick and comprehensive vascular assessment in these cases. 3) In pregnant patients, balancing imaging modality risks is crucial, with MRA serving as an alternative when necessary. Recent studies and stroke guidelines emphasize the role of CTA in acute stroke settings due to its superior resolution and rapid acquisition time. Although DOACs and other preventive measures have evolved for stroke management, detailed vascular imaging remains essential for guiding appropriate secondary prevention strategies and interventions.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Decrease risk of stroke in patient with homocysteinemia",
    "option_a": "(Vitamin B1) supports carbohydrate metabolism rather than homocysteine clearance. Option b (Coenzyme Q10) plays a role in mitochondrial function and antioxidant defense but does not lower homocysteine levels. Option d (Carnitine) is involved in fatty acid transport and energy metabolism without an impact on homocysteine metabolism. Only option c (Vitamin B6) directly aids the enzyme",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "c",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "Hyperhomocysteinemia is associated with an increased risk of stroke because elevated homocysteine levels can damage blood vessels and promote thrombosis. Vitamin B6 (pyridoxine) is a critical cofactor in the transsulfuration pathway, converting homocysteine into cystathionine, thereby reducing plasma homocysteine levels. The accumulation of homocysteine leads to endothelial dysfunction, proinflammatory changes, and a propensity for thrombus formation. Vitamin B6 facilitates the activity of cystathionine \u03b2-synthase, which metabolizes homocysteine into cystathionine. This metabolic conversion is vital for maintaining lower levels of homocysteine and decreasing the vascular injury that predisposes patients to stroke. Patients with elevated homocysteine levels are at higher risk for stroke and other cardiovascular events. Supplementation with vitamin B6 can help lower homocysteine levels, reducing stroke risk. This approach is part of a broader strategy that may also include folate and vitamin B12 supplementation, along with lifestyle and dietary modifications. Diagnosing hyperhomocysteinemia involves plasma homocysteine measurement and identifying underlying causes such as nutritional deficiencies, genetic mutations (e.g., MTHFR), or renal insufficiency. Differential diagnoses include other metabolic causes of vascular disease. Laboratory evaluation is key to tailoring therapy. Management begins with vitamin supplementation: first-line therapy typically includes vitamin B6 (along with folate and vitamin B12 when indicated) to correct the metabolic defect. In addition, controlling other stroke risk factors through lifestyle changes and medications is essential. In pregnancy, folate supplementation is critical to prevent neural tube defects, and vitamin B6 is generally considered safe though should be dosed appropriately. During lactation, supplementation is usually well tolerated but must be monitored according to clinical guidelines. Option a (Vitamin B1) supports carbohydrate metabolism rather than homocysteine clearance. Option b (Coenzyme Q10) plays a role in mitochondrial function and antioxidant defense but does not lower homocysteine levels. Option d (Carnitine) is involved in fatty acid transport and energy metabolism without an impact on homocysteine metabolism. Only option c (Vitamin B6) directly aids the enzyme-mediated clearance of homocysteine, making it the correct choice. 1. Elevated homocysteine is an independent risk factor for stroke. 2. Vitamin B6 is crucial in lowering homocysteine via the transsulfuration pathway. 3. A comprehensive approach often includes folate and B12 alongside B6. Recent studies have underscored the biological rationale for lowering homocysteine with B vitamin supplementation, although clinical trials have shown mixed results regarding direct stroke prevention. Current guidelines still support correcting vitamin deficiencies in patients with hyperhomocysteinemia as part of an overall cardiovascular risk reduction strategy.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Patient was not able to read his handwriting",
    "option_a": "(ACA) would more likely cause contralateral leg weakness and cognitive changes rather than isolated visual processing deficits. Option b (MCA) is associated with hemiparesis and language deficits. Option c (ICA) would result in broader deficits by affecting multiple cerebral territories. Option d (PCA) directly supplies the occipital lobe, clarifying the visual disturbance observed.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "d",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "The posterior cerebral artery (PCA) supplies the occipital lobe and visual association areas. Damage to these regions typically results in visual processing deficits rather than classical language deficits. An ischemic event in the PCA territory affects the occipital cortex, including regions essential for visual recognition and processing. This can produce specific syndromes such as alexia (inability to read) without agraphia, where reading is impaired while writing remains intact. A patient presenting with an inability to read his own handwriting suggests a deficit in visual processing rather than motor or language dysfunction. This localization is more consistent with a lesion in the visual cortex supplied by the PCA. Neuroimaging, especially MRI, is paramount for identifying infarcts in the occipital lobes. Differential diagnoses include strokes in the MCA territory (which more commonly cause aphasia and hemiparesis) or ACA territory (which more often lead to leg weakness and frontal lobe changes). Detailed clinical assessment combined with imaging helps to localize the lesion accurately. Acute management involves standard stroke protocols, including the potential use of thrombolytic therapy if within the appropriate window. Secondary prevention includes the use of antiplatelet agents, statin therapy, and control of vascular risk factors. In pregnant or lactating patients, careful selection of medications is required; low-dose aspirin is typically acceptable, and adjustments may be made based on individual risk profiles. Option a (ACA) would more likely cause contralateral leg weakness and cognitive changes rather than isolated visual processing deficits. Option b (MCA) is associated with hemiparesis and language deficits. Option c (ICA) would result in broader deficits by affecting multiple cerebral territories. Option d (PCA) directly supplies the occipital lobe, clarifying the visual disturbance observed. 1. PCA infarcts are commonly linked with visual field deficits and reading impairments. 2. Alexia without agraphia is a hallmark of occipital lobe involvement. 3. Differentiating stroke territories is critical for accurate diagnosis and management. Advances in imaging have improved localization of infarcts, and current guidelines emphasize the tailored management of posterior circulation strokes. Recent research continues to refine the indications for thrombolytic therapy and secondary prevention strategies in these patients.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Post of aortic surgery awake with flaccid paraparesis & sensory level",
    "option_a": "",
    "option_b": "(T8) is correct because of the typical anatomical origin of the artery of Adamkiewicz in this region. Option a (T4) would suggest a higher level infarct, which is less common in this scenario; option c (L4) is below the termination of the spinal cord; and option d (C2) is inconsistent with the clinical presentation focused on lower extremity involvement.",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "b",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "Spinal cord ischemia is a known complication after aortic surgery, primarily due to compromised blood flow through the artery of Adamkiewicz, which is the major arterial supply to the anterior spinal cord. The artery of Adamkiewicz most commonly originates between T8 and L1. Its disruption during aortic surgery can lead to anterior spinal artery syndrome, resulting in flaccid paraparesis and a clear sensory level at the corresponding spinal segment due to ischemia of the anterior two-thirds of the spinal cord. Postoperative patients presenting with flaccid paraparesis and a defined sensory level have classic findings for spinal cord ischemia. The level of sensory loss typically correlates with the location of the compromised arterial blood supply. Diagnosis is based on clinical examination and is confirmed with MRI of the spine. Differential diagnoses include spinal epidural hematoma, transverse myelitis, or mechanical compression, but the temporal relationship to aortic surgery and the level-specific deficit point toward ischemia. Management is primarily supportive and aimed at optimizing perfusion pressure, including strategies such as blood pressure augmentation and, in some cases, cerebrospinal fluid drainage. In high-risk patients, careful intraoperative monitoring and protective strategies are used. In pregnant patients, maintaining spinal cord perfusion through judicious hemodynamic management is essential, while similar principles apply in lactating patients with attention to supportive care. Option b (T8) is correct because of the typical anatomical origin of the artery of Adamkiewicz in this region. Option a (T4) would suggest a higher level infarct, which is less common in this scenario; option c (L4) is below the termination of the spinal cord; and option d (C2) is inconsistent with the clinical presentation focused on lower extremity involvement. 1. The artery of Adamkiewicz generally arises between T8 and L1, making these levels most vulnerable post-aortic surgery. 2. A clear sensory level is indicative of a localized cord lesion. 3. Early recognition of spinal cord ischemia is critical for improving outcomes. Recent improvements in aortic surgical techniques and intraoperative monitoring have emphasized the need to protect spinal cord perfusion. Updated guidelines recommend measures like cerebrospinal fluid drainage and blood pressure optimization to reduce the incidence of postoperative spinal cord ischemia.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "75 year old female, DM and HTN, came with Rt sided weakness since one week, MRI: Lt internal capsule lacunar infarction, vascular workup: Rt ICA 55 % stenosis & Lt ICA of 65 % stenosis. What to do for her regarding stroke prevention",
    "option_a": "(Right ICA stenting) and option b (Left ICA stenting) are not indicated because both stenoses are moderate and asymptomatic relative to the lacunar stroke pathophysiology. Option c (Maximize medical treatment) is appropriate, as current guidelines support intensive medical management for lacunar strokes.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "c",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "Lacunar strokes are a type of small vessel cerebrovascular disease and are often the result of chronic conditions such as hypertension and diabetes. They differ from large vessel strokes caused by significant atherosclerotic disease. Lacunar infarcts occur due to occlusion of small penetrating arteries that supply deep brain structures such as the internal capsule. The moderate carotid stenoses in this patient (55% and 65%) are typically insufficient to cause embolic strokes, particularly when the clinical picture is that of a lacunar infarct. In elderly patients with risk factors like diabetes and hypertension, lacunar strokes are common. The presentation with an internal capsule lacunar infarction and moderate carotid stenosis supports the diagnosis of a small vessel stroke rather than an embolic event from significant carotid atherosclerosis. Diagnosis is made based on clinical findings and imaging studies (MRI) that reveal small, deep infarcts. Differential diagnoses include embolic strokes from significant carotid stenosis or cortical infarcts, but the absence of high-grade stenosis or cortical involvement makes a lacunar stroke more likely. The first-line treatment is aggressive medical management. This includes antiplatelet therapy (aspirin and/or clopidogrel), high-intensity statin therapy, optimal control of blood pressure and blood sugar, and lifestyle modifications. Carotid stenting or endarterectomy is generally reserved for symptomatic high-grade stenosis (typically >70%). In pregnant or lactating patients, medical management is adjusted with agents proven safe in these groups; low-dose aspirin is often acceptable with careful monitoring. Option a (Right ICA stenting) and option b (Left ICA stenting) are not indicated because both stenoses are moderate and asymptomatic relative to the lacunar stroke pathophysiology. Option c (Maximize medical treatment) is appropriate, as current guidelines support intensive medical management for lacunar strokes. 1. Lacunar strokes result from small vessel disease, not embolism from carotid stenosis. 2. Moderate carotid stenosis does not typically warrant revascularization in the context of lacunar infarction. 3. Risk factor modification is key to preventing recurrent stroke. Recent trials and guidelines emphasize that aggressive medical management is superior to invasive interventions in the setting of lacunar strokes. Ongoing research supports the role of strict blood pressure, glycemic, and lipid control in reducing the risk of future cerebrovascular events.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "82-year-old, medically free, came with acute right-side weakness and global aphasia for 3 hours, BP 180/100mmHg, his CT scan is shown (no hemorrhage, with good ASPECT scores). What is your next step in his management?",
    "option_a": "(reduce BP) is incorrect because although the patient is hypertensive, his blood pressure is still below the critical threshold that mandates immediate lowering prior to tPA. Option B (IV thrombolytic) is the correct and time",
    "option_b": "",
    "option_c": "(CTA) is valuable in later planning for endovascular therapy but should not delay the administration of thrombolysis in eligible patients.",
    "option_d": "",
    "option_e": "",
    "correct_answer": "b",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "Acute ischemic stroke management relies on rapid identification and revascularization to salvage the ischemic penumbra. The patient, presenting within 3 hours of symptom onset with CT imaging that excludes hemorrhage and shows a high ASPECTS score, meets the criteria for thrombolytic therapy. Ischemic strokes occur when an occlusive thrombus or embolus disrupts cerebral blood flow, leading to a core of irreversibly injured tissue surrounded by a penumbra that is at risk yet salvageable. Intravenous thrombolytics (tPA) catalyze the conversion of plasminogen to plasmin, lysing the clot and restoring perfusion. Inappropriately lowering blood pressure can reduce perfusion in the penumbra and worsen injury. The patient\u2019s global aphasia and right-sided weakness suggest a dominant hemisphere (likely left MCA territory) infarct. His blood pressure of 180/100 mmHg, although high, is below the threshold of 185/110 mmHg that necessitates urgent control before thrombolytic administration. His CT findings (absence of hemorrhage, good ASPECTS) further affirm that thrombolysis is appropriate. The immediate use of non-contrast head CT is critical to exclude hemorrhage. Differential diagnoses include hemorrhagic stroke (ruled out by CT), stroke mimics (e.g., seizures, migraine), and other intracranial emergencies. Advanced imaging like CTA may be used subsequently to assess large vessel occlusion but should not delay thrombolysis. First-line management is intravenous thrombolysis (tPA) if administered within the therapeutic window (currently recommended within 4.5 hours, with greatest benefit within 3 hours) after excluding contraindications such as intracranial hemorrhage. Blood pressure should be maintained below 185/110 mmHg prior to tPA. Endovascular intervention is reserved for patients with large vessel occlusion who may benefit from thrombectomy. In pregnant patients, tPA has been used cautiously when benefits outweigh risks, and in lactating patients tPA is also considered acceptable with appropriate counseling. Option A (reduce BP) is incorrect because although the patient is hypertensive, his blood pressure is still below the critical threshold that mandates immediate lowering prior to tPA. Option B (IV thrombolytic) is the correct and time-sensitive treatment. Option C (CTA) is valuable in later planning for endovascular therapy but should not delay the administration of thrombolysis in eligible patients. 1. The therapeutic window for IV tPA is narrow; prompt imaging and treatment initiation are essential. 2. A good ASPECTS score indicates a smaller infarct core, suggesting a greater benefit from reperfusion therapies. 3. Blood pressure management is crucial: avoid unnecessary lowering if BP is below 185/110 mmHg prior to tPA. Recent AHA/ASA guidelines continue to support the use of IV thrombolytics in eligible patients within the specified time window, emphasizing rapid treatment to reduce long-term disability. Ongoing research into extended windows for mechanical thrombectomy complements these guidelines without altering the need for immediate tPA in eligible patients.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "50-year-old transient Rt side weakness, Dx: TIA, Rt ICA 60%, Lt 65% stenosis",
    "option_a": "(Aspirin alone) is correct because it is the cornerstone of medical management in patients with moderate symptomatic carotid stenosis. Option B (Angioplasty alone) is not standard due to high rates of restenosis and embolic risks. Option C (Dual antiplatelet therapy) is not required for long",
    "option_b": "",
    "option_c": "",
    "option_d": "(Angioplasty with stenting) is generally reserved for high",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "Transient ischemic attacks (TIAs) serve as a warning sign for future stroke and are most often due to emboli from atherosclerotic plaques. In patients with moderate carotid stenosis (60-65%), the focus is on medical management to stabilize the plaque and prevent embolization. TIAs result from transient reductions in cerebral blood flow, often due to emboli from unstable atherosclerotic plaques in the carotid arteries. Platelet aggregation plays a crucial role in the formation and propagation of these emboli. A 50-year-old patient with a TIA and moderate carotid stenosis typically presents with transient neurological deficits. Since the degree of stenosis is not high-grade (70% or more), the risk of recurrent stroke can be minimized through conservative, medical management. Diagnosis includes neurological evaluation, brain imaging (CT or MRI) to exclude infarction, and carotid duplex ultrasonography to quantify the degree of stenosis. Differential diagnoses include small vessel (lacunar) disease and cardioembolic sources, which can be differentiated by additional imaging and cardiac workup. First-line management includes initiating antiplatelet therapy with aspirin to reduce platelet aggregation and the risk of future strokes. Aggressive risk factor modification (control of hypertension, diabetes, dyslipidemia, and smoking cessation) is also essential. Dual antiplatelet therapy may be considered short-term in specific acute cases but is not indicated for long-term management of moderate stenosis. Invasive procedures like carotid stenting or endarterectomy are reserved for high-grade stenosis (\u226570%) or when patients have recurrent symptoms despite optimal medical therapy. For pregnant or lactating women, low-dose aspirin is generally recommended when the benefits outweigh the risks, although the risk\u2013benefit profile must be carefully assessed. Option A (Aspirin alone) is correct because it is the cornerstone of medical management in patients with moderate symptomatic carotid stenosis. Option B (Angioplasty alone) is not standard due to high rates of restenosis and embolic risks. Option C (Dual antiplatelet therapy) is not required for long-term management in this scenario because it increases bleeding risk without clear benefit over aspirin monotherapy. Option D (Angioplasty with stenting) is generally reserved for high-grade stenosis (\u226570%) or patients who are poor surgical candidates. 1. Aspirin is the first-line therapy in most TIAs to reduce the risk of stroke. 2. Moderate carotid stenosis (less than 70%) is best managed medically rather than invasively. 3. Aggressive management of vascular risk factors is essential to prevent future cerebrovascular events. Current guidelines from the American Stroke Association recommend aspirin monotherapy for patients with symptomatic carotid artery stenosis below 70%. Recent studies continue to validate the safety and efficacy of medical management in these patients while reserving endarterectomy or stenting for those with severe stenosis.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "30 y.o male found unconscious at street. What you expect as the mechanism of injury for attached CT",
    "option_a": "(Aneurysmal) is incorrect because aneurysmal ruptures typically produce subarachnoid hemorrhage in a non",
    "option_b": "(Trauma) is correct as the patient\u2019s history and clinical situation strongly indicate a traumatic injury. Option C (Hypertension) is incorrect because hypertensive hemorrhages generally occur in older individuals with a history of poorly controlled blood pressure and typically involve deep brain regions.",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "b",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "This case involves a young male found unconscious outdoors, which strongly suggests a traumatic mechanism. In trauma cases, the evaluation focuses on identifying intracranial injuries such as hematomas, contusions, or diffuse axonal injury. Traumatic brain injuries (TBIs) result from external mechanical forces that disrupt normal cerebral function. Vessel rupture due to blunt force trauma can lead to various hemorrhages (e.g., epidural, subdural) and parenchymal contusions. A 30-year-old male found unconscious is more likely to have suffered head trauma rather than a spontaneous hemorrhage from hypertension or an aneurysmal rupture. The CT appearance in traumatic injury typically includes localized hemorrhages or contusions, often with a pattern distinct from spontaneous bleeds seen in hypertensive or aneurysmal events. Immediate non-contrast CT imaging is used to identify intracranial hemorrhages and traumatic injuries. Differential diagnoses include aneurysmal subarachnoid hemorrhage (which usually presents with a severe headache and a different bleeding pattern on CT) and hypertensive hemorrhage (characteristically seen in older patients with chronic hypertension involving deep brain structures). Management of TBI includes rapid neurosurgical evaluation, maintenance of airway, breathing, and circulation, and intracranial pressure monitoring when indicated. Surgical intervention may be necessary if there is significant hematoma with mass effect. In pregnant patients, imaging protocols are adjusted to minimize fetal exposure while ensuring maternal safety, and similar principles apply for lactating patients with careful counseling regarding radiation exposure. Option A (Aneurysmal) is incorrect because aneurysmal ruptures typically produce subarachnoid hemorrhage in a non-traumatic context with a characteristic severe headache. Option B (Trauma) is correct as the patient\u2019s history and clinical situation strongly indicate a traumatic injury. Option C (Hypertension) is incorrect because hypertensive hemorrhages generally occur in older individuals with a history of poorly controlled blood pressure and typically involve deep brain regions. 1. In young patients found unconscious, always consider trauma as the primary cause of intracranial injury. 2. CT imaging is crucial to distinguishing between traumatic and spontaneous intracranial hemorrhages. 3. Traumatic hemorrhages have characteristic CT patterns that differ from hypertensive or aneurysmal bleeds. Recent trauma guidelines stress the importance of rapid CT imaging for TBI evaluation and emphasize early neurosurgical consultation. Ongoing research is focused on minimizing radiation exposure in vulnerable populations, such as pregnant women, while ensuring accurate diagnosis.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Global aphasia after one month (? asking about prognosis)",
    "option_a": "(Broca\u2019s aphasia) is incorrect because it represents a less severe, non",
    "option_b": "(Global aphasia) is correct, reflecting the patient\u2019s persistent and extensive language deficits. Option C (Anomia) is incorrect as it refers only to word",
    "option_c": "",
    "option_d": "(Wernicke\u2019s aphasia) is incorrect because it does not match the global nature of the deficits observed.",
    "option_e": "",
    "correct_answer": "b",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "Aphasia is a language disorder caused by damage to specific regions of the brain. Global aphasia involves severe impairment in both expressive and receptive language functions. Persistence of global aphasia after one month indicates extensive cortical damage, generally implying a poorer prognosis. Global aphasia results from large lesions that affect essential language centers, typically involving both Broca\u2019s (expressive) and Wernicke\u2019s (receptive) areas, often due to a large middle cerebral artery (MCA) infarct. The extensive damage disrupts communication networks in the brain, leading to profound language deficits. A patient with persistent global aphasia at one month post-stroke is unlikely to have transitioned to a less severe form such as Broca\u2019s or Wernicke\u2019s aphasia. This sustained deficit reflects a large area of infarction with limited potential for rapid recovery. Evaluation includes detailed language assessments performed by a speech-language pathologist and correlating neuroimaging studies (CT/MRI) to determine the extent of cortical damage. Differential diagnoses in aphasia include Broca\u2019s aphasia (non-fluent, relatively preserved comprehension), Wernicke\u2019s aphasia (fluent but with impaired comprehension), and anomic aphasia (word-finding difficulties with milder deficits). The mainstay of management for aphasia is intensive, early speech and language therapy. While prognosis in global aphasia is guarded, early rehabilitation, multidisciplinary care, and patient-specific interventions can optimize functional recovery. For pregnant and lactating patients, non-invasive treatments such as speech therapy are safe and remain the standard of care. Option A (Broca\u2019s aphasia) is incorrect because it represents a less severe, non-fluent aphasia with relatively preserved comprehension. Option B (Global aphasia) is correct, reflecting the patient\u2019s persistent and extensive language deficits. Option C (Anomia) is incorrect as it refers only to word-finding difficulties, and Option D (Wernicke\u2019s aphasia) is incorrect because it does not match the global nature of the deficits observed. 1. Persistent global aphasia after one month typically indicates a large infarct with a poorer prognosis. 2. Early, aggressive speech and language therapy is crucial, though recovery may be limited. 3. Detailed language assessments help to monitor recovery and tailor rehabilitative efforts. Recent research emphasizes the role of neuroplasticity and early intervention in post-stroke aphasia. Although recovery in global aphasia remains challenging, emerging therapies and advanced neurorehabilitation techniques continue to evolve, with ongoing studies investigating adjuvant therapies to improve outcomes.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Small PFO & AF in young female who developed stroke, ttt",
    "option_a": "(Closure): Incorrect because closing a small PFO does not address the embolic risk from AF. Option b (Warfarin): While anticoagulation is indicated in many AF cases, warfarin is not preferred given the availability of DOACs and may be overtreatment in a low AF burden scenario. Option c (ASA): Correct in this context where the clinical scenario implies low AF burden or diagnostic uncertainty, making antiplatelet therapy a conservative and appropriate choice.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "c",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "This question concerns the management of stroke in a young female with a small patent foramen ovale (PFO) and atrial fibrillation (AF). The key concept is discerning the stroke source. In patients with cryptogenic stroke and a small PFO, closure is typically reserved when no other embolic source exists. However, when AF is present\u2014even if paroxysmal or of low burden\u2014it can be considered a source of cardioembolism. In selected cases, especially when the AF burden isn\u2019t definitively high or when its role is ambiguous, a conservative approach with antiplatelet therapy may be chosen. A small PFO permits the possibility of paradoxical embolism, but its risk is generally lower compared to a significant shunt. In atrial fibrillation, stasis in the left atrium promotes thrombus formation that may embolize to the brain. When both conditions coexist, the underlying pathophysiological concern is determining which source is dominant. Current evidence suggests that in patients with low-risk AF or uncertainty about stroke mechanism, aggressive anticoagulation may not provide additional benefit compared to antiplatelet therapy, particularly if the PFO is small. Clinically, a young stroke patient might present with focal neurologic deficits and workup may reveal a small PFO on echocardiography and episodes of paroxysmal AF on prolonged monitoring. The decision for treatment is influenced by the frequency and burden of AF as well as the anatomical significance of the PFO. The clinical challenge lies in attributing the stroke to either a paradoxical embolism via PFO or an embolism from AF. Evaluation includes brain imaging (MRI/CT) to confirm infarction, transthoracic or transesophageal echocardiography to assess for PFO, and cardiac monitoring (e.g., Holter) for detecting paroxysmal AF. Differential diagnoses include other causes of cryptogenic stroke such as hypercoagulable states, arterial dissection, and vasculitis. Differentiation relies on combining imaging studies with clinical risk factor assessments. Latest guidelines recommend antiplatelet therapy (aspirin) for secondary prevention in patients with low-risk or uncertain sources where the burden of AF is minimal. First-line treatment is usually aspirin, particularly in younger patients or those in whom the risk\u2013benefit profile for full anticoagulation is unclear. In contrast, patients with definite, sustained AF typically require anticoagulation with direct oral anticoagulants (DOACs), which are preferred over warfarin for their predictable effect and safety profile. In pregnancy and lactation, low-dose aspirin is generally considered safe, although the decision must account for individual patient risk factors and breastfeeding status. Option a (Closure): Incorrect because closing a small PFO does not address the embolic risk from AF. Option b (Warfarin): While anticoagulation is indicated in many AF cases, warfarin is not preferred given the availability of DOACs and may be overtreatment in a low AF burden scenario. Option c (ASA): Correct in this context where the clinical scenario implies low AF burden or diagnostic uncertainty, making antiplatelet therapy a conservative and appropriate choice. 1. In patients with cryptogenic stroke, discerning the stroke source (PFO vs. AF) is essential to guide management. 2. PFO closure is generally reserved for patients without another clear embolic source. 3. Low-dose aspirin is relatively safe in young patients and during pregnancy/lactation when full anticoagulation is not clearly indicated. Recent studies and guidelines continue to stress the need for individualized therapy in stroke management. The data support the use of DOACs in definitive AF cases, whereas in cryptogenic stroke with a small PFO and minimal AF burden, aspirin remains a viable first-line option. Ongoing research is further refining criteria to differentiate stroke sources.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Lobar hemorrhage with high INR, ttt:",
    "option_a": "(PCC): Correct",
    "option_b": "(FFP): Incorrect",
    "option_c": "(Vitamin K alone): Incorrect",
    "option_d": "(Protamine): Incorrect",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "This question deals with the acute management of warfarin-associated intracerebral hemorrhage (ICH) in a patient with a lobar hemorrhage and an elevated International Normalized Ratio (INR). The primary goal is rapid reversal of the coagulopathy to prevent hematoma expansion and further neurological injury. Warfarin interferes with the synthesis of vitamin K\u2013dependent clotting factors (II, VII, IX, and X). In the setting of an intracranial hemorrhage, the lack of these factors prolongs bleeding. Prothrombin complex concentrates (PCC) provide concentrated clotting factors, rapidly normalizing the INR and thereby limiting further bleeding. Patients on warfarin presenting with lobar hemorrhage require urgent correction of their coagulopathy. A high INR correlates with an increased risk of bleeding expansion. Timely reversal can mitigate hematoma growth and improve clinical outcomes. Initial workup includes a non-contrast head CT confirming hemorrhage, laboratory testing to determine INR and coagulation status, and a careful review of the medication history. Differential diagnoses include hemorrhagic transformation of an ischemic stroke and other coagulopathies. Current guidelines recommend using PCC as first-line therapy because of its rapid action in reversing warfarin-induced coagulopathy. Vitamin K should be administered concurrently to achieve sustained reversal, although its onset is delayed (6\u201324 hours). Fresh frozen plasma (FFP) is a secondary option if PCC is unavailable due to its slower action and larger volume requirements. Protamine sulfate is reserved for the reversal of heparin and has no effect on warfarin reversal. In pregnancy and lactation, rapid reversal remains critical; PCC along with vitamin K is used despite warfarin\u2019s contraindication in pregnancy, as the acute situation mandates reversal of coagulopathy. Option a (PCC): Correct \u2013 Provides rapid reversal of warfarin\u2019s effects by delivering clotting factors. Option b (FFP): Incorrect \u2013 Although it provides clotting factors, its slower action and higher volume load make it less desirable in an acute setting. Option c (Vitamin K alone): Incorrect \u2013 While necessary for sustained reversal, its delayed onset precludes its use as the sole agent in acute hemorrhage management. Option d (Protamine): Incorrect \u2013 Protamine reverses heparin, not warfarin. 1. PCC is the fastest means to reverse warfarin-induced coagulopathy in acute ICH. 2. Always use vitamin K alongside PCC for prolonged reversal. 3. Distinguish between warfarin reversal agents and those used for heparin. Recent guidelines from the American Heart Association emphasize that PCC is preferred over FFP for reversing warfarin-associated ICH due to its rapid efficacy and lower complication profile. Studies have reinforced its use in improving clinical outcomes by rapidly restoring coagulation.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Severe MCA stenosis in elderly with stroke, ttt",
    "option_a": "(ASA): Correct",
    "option_b": "(Angio & stenting): Incorrect",
    "option_c": "(ASA & Warfarin): Incorrect",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "This question focuses on the management of severe middle cerebral artery (MCA) stenosis in an elderly patient with stroke. The central principle is that medical management, primarily with antiplatelet therapy, is the mainstay of treatment for intracranial atherosclerotic disease. Severe MCA stenosis is usually the result of atherosclerotic plaque buildup, which may lead to turbulent flow and a propensity for thrombosis. This mechanism increases the risk of ischemic stroke by limiting cerebral perfusion and facilitating embolism from unstable plaques. Patients typically present with symptoms of ischemic stroke such as hemiparesis, aphasia, or sensory deficits. Imaging (CT/MRI angiography) identifies the degree of stenosis. Recognizing the underlying pathology directs the treatment toward limiting further ischemic events while managing vascular risk factors. The diagnostic workup involves brain imaging to document the stroke and vascular studies (MRA, CTA, or catheter angiography) to assess the severity of intracranial stenosis. Differential diagnoses include embolic stroke from cardiac sources and small vessel lacunar infarcts. Risk factor evaluation (hypertension, diabetes, hyperlipidemia) is essential. First-line management is aggressive medical therapy, which includes antiplatelet agents (aspirin as the cornerstone), risk factor modification (blood pressure, lipid control), and lifestyle changes. Second-line therapies (such as angioplasty and stenting) are generally reserved for patients who fail optimal medical therapy and are approached with caution due to periprocedural risks. In pregnancy and lactation, aspirin (in low-dose form) is typically considered safe for stroke prevention, whereas invasive procedures are usually deferred unless absolutely necessary. Option a (ASA): Correct \u2013 Aspirin is the recommended first-line antiplatelet therapy supported by evidence from trials like SAMMPRIS and WASID. Option b (Angio & stenting): Incorrect \u2013 Invasive procedures carry a high risk and are not first-line due to increased periprocedural complications. Option c (ASA & Warfarin): Incorrect \u2013 Combining anticoagulation with antiplatelet therapy has not been shown to be superior to antiplatelet monotherapy and increases the risk of hemorrhage. 1. Aspirin remains the cornerstone in the management of intracranial atherosclerotic disease. 2. Invasive procedures should be reserved for refractory cases, given the high associated risks. 3. Optimal management includes aggressive control of vascular risk factors. Recent clinical trials such as SAMMPRIS and WASID reinforce that aggressive medical management, particularly with antiplatelet therapy, is superior to invasive interventions in patients with severe MCA stenosis. Current guidelines continue to endorse aspirin as the primary antiplatelet agent in this setting.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Maxillary, nasal lesion with proptosis, causes of CVT:",
    "option_a": "(Direct invasion): Correct",
    "option_b": "(Veins): Incorrect",
    "option_c": "",
    "option_d": "oes not explain the mechanism. Option c (LN [Lymph nodes]): Incorrect",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "This question examines the mechanism by which maxillary or nasal lesions that produce proptosis can lead to cerebral venous thrombosis (CVT). The central concept is the potential for direct extension of infection or malignancy from adjacent extracranial structures to intracranial venous sinuses. Maxillary or nasal lesions, particularly those with an invasive component, may extend directly into the cerebral venous system. The valveless venous networks interconnect the extracranial and intracranial compartments, allowing pathogens or tumor cells to directly invade the dural sinuses, causing endothelial injury and subsequent thrombosis. Patients with such lesions typically present with signs of orbital involvement like proptosis, headache, and sometimes visual disturbances. CVT may present with additional symptoms including seizures and altered mental status. Recognizing direct invasive spread is crucial for early diagnosis and management. Diagnostic imaging plays a vital role. Magnetic resonance venography (MRV) or CT venography (CTV) can delineate the presence of thrombosis. Differentiation from other causes of proptosis (e.g., orbital cellulitis, cavernous sinus thrombosis from other etiologies) is achieved by correlating clinical history with imaging findings. The primary treatment is anticoagulation to prevent thrombus propagation, even in the context of hemorrhagic transformation, along with addressing the underlying lesion (via antibiotics, surgery, or oncological management). In the setting of pregnancy and lactation, low molecular weight heparin is commonly used for CVT due to its safety profile compared to unfractionated heparin or warfarin. Option a (Direct invasion): Correct \u2013 It accurately describes the mechanism by which a maxillary, nasal lesion with proptosis causes CVT via anatomical venous connections. Option b (Veins): Incorrect \u2013 Too vague; while veins are the site of thrombosis, this option does not explain the mechanism. Option c (LN [Lymph nodes]): Incorrect \u2013 Lymphatic structures do not directly communicate with the intracranial venous system and are not involved in the pathogenesis of CVT in this scenario. 1. Direct extension of infection or malignancy through valveless venous channels is a well-known cause of CVT. 2. Proptosis in the setting of nasal or maxillary lesions should prompt evaluation for intracranial complications. 3. Early imaging with MRV or CTV is critical in making the diagnosis. Recent clinical literature emphasizes the importance of recognizing the anatomical pathways for infection spread in the head and neck region. Updated guidelines support early anticoagulation and management of the primary lesion to improve outcomes in CVT.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "The management of a patient who developed angioedema after starting tPA:",
    "option_a": "Reassurance",
    "option_b": "intubate",
    "option_c": "anti-histamine & steroids",
    "option_d": "is not provided.",
    "option_e": "",
    "correct_answer": "c",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "Angioedema is a localized, self\u2010limited edema of the deep dermis and subcutaneous tissues. When it occurs in the context of tPA administration (often in patients with underlying ACE\u2010inhibitor use), it is thought to be secondary to an abnormal release of vasoactive mediators. The clinical scenario requires rapid recognition because swelling of the tongue, lips, or oropharynx can progress to airway compromise. tPA not only lyses fibrin clots but also activates plasmin which can trigger the release of bradykinin. Increased bradykinin levels lead to vasodilation and increased vascular permeability. Although the process is bradykinin\u2010mediated (instead of the classic histaminergic allergic reaction), many of the treatments overlap. In some cases, the reaction may be severe enough to require aggressive airway management. Patients receiving tPA for ischemic stroke may develop angioedema within the infusion period. Clinically, swelling typically involves the tongue, lips, and sometimes the floor of the mouth. Although it may start as a localized process, rapid progression can lead to difficulty breathing and potential airway loss, especially in patients with predisposing factors such as concurrent ACE inhibitor use. This diagnosis is based on clinical observation. The differential includes allergic reaction/anaphylaxis from other agents, or soft tissue infections. In the setting of recent tPA administration and a typical distribution (orolingual), tPA-induced angioedema is the most likely diagnosis. Monitoring for airway patency and assessing progression is critical. The first step in management is to immediately stop the tPA infusion. In mild cases where airway compromise is not imminent, treatment with anti-histamines (H1 blockers) and corticosteroids is recommended to reduce inflammation. Epinephrine may be considered if there are signs of a more typical anaphylactic reaction. However, if there is any concern for airway compromise, securing the airway (with intubation) is imperative. In pregnant or lactating patients, these medications are used with caution but are acceptable when maternal airway protection is needed. Consultation with anesthesia and otolaryngology may be warranted for airway management. Option A (Reassurance) is insufficient as the risk of airway compromise requires active intervention. Option B (Intubate) is reserved for cases with significant airway compromise and is not the first-line approach in the absence of severe symptoms. Option C (anti-histamine & steroids) is the appropriate first-line management for mild to moderate angioedema post-tPA, making it the correct answer. Option D is not provided. \u2022 tPA-induced angioedema is most commonly seen in patients on ACE inhibitors. \u2022 Always monitor for airway compromise and be ready to secure the airway. \u2022 Early cessation of tPA infusion is critical in the management of this complication. Recent studies and guidelines emphasize that while the angioedema associated with tPA is bradykinin-mediated, initial management with anti-histamines and steroids remains standard practice, along with vigilant airway monitoring. There is emerging interest in specific bradykinin inhibitors (like icatibant), but these are not yet standard.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "83-Year-old man, presented with 3 hr Hx of stroke, CT brain done What to do next \u0646\u0633\u064a\u062a \u062a\u0641\u0627\u0635\u064a\u0644 \u0627\u0644\u062d\u0627\u0644\u0629",
    "option_a": "(Reassurance) is insufficient as the risk of airway compromise requires active intervention. Option B (Intubate) is reserved for cases with significant airway compromise and is not the first",
    "option_b": "",
    "option_c": "(anti",
    "option_d": "is not provided.",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "Angioedema is a localized, self\u2010limited edema of the deep dermis and subcutaneous tissues. When it occurs in the context of tPA administration (often in patients with underlying ACE\u2010inhibitor use), it is thought to be secondary to an abnormal release of vasoactive mediators. The clinical scenario requires rapid recognition because swelling of the tongue, lips, or oropharynx can progress to airway compromise. tPA not only lyses fibrin clots but also activates plasmin which can trigger the release of bradykinin. Increased bradykinin levels lead to vasodilation and increased vascular permeability. Although the process is bradykinin\u2010mediated (instead of the classic histaminergic allergic reaction), many of the treatments overlap. In some cases, the reaction may be severe enough to require aggressive airway management. Patients receiving tPA for ischemic stroke may develop angioedema within the infusion period. Clinically, swelling typically involves the tongue, lips, and sometimes the floor of the mouth. Although it may start as a localized process, rapid progression can lead to difficulty breathing and potential airway loss, especially in patients with predisposing factors such as concurrent ACE inhibitor use. This diagnosis is based on clinical observation. The differential includes allergic reaction/anaphylaxis from other agents, or soft tissue infections. In the setting of recent tPA administration and a typical distribution (orolingual), tPA-induced angioedema is the most likely diagnosis. Monitoring for airway patency and assessing progression is critical. The first step in management is to immediately stop the tPA infusion. In mild cases where airway compromise is not imminent, treatment with anti-histamines (H1 blockers) and corticosteroids is recommended to reduce inflammation. Epinephrine may be considered if there are signs of a more typical anaphylactic reaction. However, if there is any concern for airway compromise, securing the airway (with intubation) is imperative. In pregnant or lactating patients, these medications are used with caution but are acceptable when maternal airway protection is needed. Consultation with anesthesia and otolaryngology may be warranted for airway management. Option A (Reassurance) is insufficient as the risk of airway compromise requires active intervention. Option B (Intubate) is reserved for cases with significant airway compromise and is not the first-line approach in the absence of severe symptoms. Option C (anti-histamine & steroids) is the appropriate first-line management for mild to moderate angioedema post-tPA, making it the correct answer. Option D is not provided. \u2022 tPA-induced angioedema is most commonly seen in patients on ACE inhibitors. \u2022 Always monitor for airway compromise and be ready to secure the airway. \u2022 Early cessation of tPA infusion is critical in the management of this complication. Recent studies and guidelines emphasize that while the angioedema associated with tPA is bradykinin-mediated, initial management with anti-histamines and steroids remains standard practice, along with vigilant airway monitoring. There is emerging interest in specific bradykinin inhibitors (like icatibant), but these are not yet standard.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Tongue deviation to the Lt",
    "option_a": "(Reassurance) is insufficient as the risk of airway compromise requires active intervention. Option B (Intubate) is reserved for cases with significant airway compromise and is not the first",
    "option_b": "",
    "option_c": "(anti",
    "option_d": "is not provided.",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "Angioedema is a localized, self\u2010limited edema of the deep dermis and subcutaneous tissues. When it occurs in the context of tPA administration (often in patients with underlying ACE\u2010inhibitor use), it is thought to be secondary to an abnormal release of vasoactive mediators. The clinical scenario requires rapid recognition because swelling of the tongue, lips, or oropharynx can progress to airway compromise. tPA not only lyses fibrin clots but also activates plasmin which can trigger the release of bradykinin. Increased bradykinin levels lead to vasodilation and increased vascular permeability. Although the process is bradykinin\u2010mediated (instead of the classic histaminergic allergic reaction), many of the treatments overlap. In some cases, the reaction may be severe enough to require aggressive airway management. Patients receiving tPA for ischemic stroke may develop angioedema within the infusion period. Clinically, swelling typically involves the tongue, lips, and sometimes the floor of the mouth. Although it may start as a localized process, rapid progression can lead to difficulty breathing and potential airway loss, especially in patients with predisposing factors such as concurrent ACE inhibitor use. This diagnosis is based on clinical observation. The differential includes allergic reaction/anaphylaxis from other agents, or soft tissue infections. In the setting of recent tPA administration and a typical distribution (orolingual), tPA-induced angioedema is the most likely diagnosis. Monitoring for airway patency and assessing progression is critical. The first step in management is to immediately stop the tPA infusion. In mild cases where airway compromise is not imminent, treatment with anti-histamines (H1 blockers) and corticosteroids is recommended to reduce inflammation. Epinephrine may be considered if there are signs of a more typical anaphylactic reaction. However, if there is any concern for airway compromise, securing the airway (with intubation) is imperative. In pregnant or lactating patients, these medications are used with caution but are acceptable when maternal airway protection is needed. Consultation with anesthesia and otolaryngology may be warranted for airway management. Option A (Reassurance) is insufficient as the risk of airway compromise requires active intervention. Option B (Intubate) is reserved for cases with significant airway compromise and is not the first-line approach in the absence of severe symptoms. Option C (anti-histamine & steroids) is the appropriate first-line management for mild to moderate angioedema post-tPA, making it the correct answer. Option D is not provided. \u2022 tPA-induced angioedema is most commonly seen in patients on ACE inhibitors. \u2022 Always monitor for airway compromise and be ready to secure the airway. \u2022 Early cessation of tPA infusion is critical in the management of this complication. Recent studies and guidelines emphasize that while the angioedema associated with tPA is bradykinin-mediated, initial management with anti-histamines and steroids remains standard practice, along with vigilant airway monitoring. There is emerging interest in specific bradykinin inhibitors (like icatibant), but these are not yet standard.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Case of chronic fluctuating paraparesis\nimage attached",
    "option_a": "(Reassurance) is insufficient as the risk of airway compromise requires active intervention. Option B (Intubate) is reserved for cases with significant airway compromise and is not the first",
    "option_b": "",
    "option_c": "(anti",
    "option_d": "is not provided.",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "Angioedema is a localized, self\u2010limited edema of the deep dermis and subcutaneous tissues. When it occurs in the context of tPA administration (often in patients with underlying ACE\u2010inhibitor use), it is thought to be secondary to an abnormal release of vasoactive mediators. The clinical scenario requires rapid recognition because swelling of the tongue, lips, or oropharynx can progress to airway compromise. tPA not only lyses fibrin clots but also activates plasmin which can trigger the release of bradykinin. Increased bradykinin levels lead to vasodilation and increased vascular permeability. Although the process is bradykinin\u2010mediated (instead of the classic histaminergic allergic reaction), many of the treatments overlap. In some cases, the reaction may be severe enough to require aggressive airway management. Patients receiving tPA for ischemic stroke may develop angioedema within the infusion period. Clinically, swelling typically involves the tongue, lips, and sometimes the floor of the mouth. Although it may start as a localized process, rapid progression can lead to difficulty breathing and potential airway loss, especially in patients with predisposing factors such as concurrent ACE inhibitor use. This diagnosis is based on clinical observation. The differential includes allergic reaction/anaphylaxis from other agents, or soft tissue infections. In the setting of recent tPA administration and a typical distribution (orolingual), tPA-induced angioedema is the most likely diagnosis. Monitoring for airway patency and assessing progression is critical. The first step in management is to immediately stop the tPA infusion. In mild cases where airway compromise is not imminent, treatment with anti-histamines (H1 blockers) and corticosteroids is recommended to reduce inflammation. Epinephrine may be considered if there are signs of a more typical anaphylactic reaction. However, if there is any concern for airway compromise, securing the airway (with intubation) is imperative. In pregnant or lactating patients, these medications are used with caution but are acceptable when maternal airway protection is needed. Consultation with anesthesia and otolaryngology may be warranted for airway management. Option A (Reassurance) is insufficient as the risk of airway compromise requires active intervention. Option B (Intubate) is reserved for cases with significant airway compromise and is not the first-line approach in the absence of severe symptoms. Option C (anti-histamine & steroids) is the appropriate first-line management for mild to moderate angioedema post-tPA, making it the correct answer. Option D is not provided. \u2022 tPA-induced angioedema is most commonly seen in patients on ACE inhibitors. \u2022 Always monitor for airway compromise and be ready to secure the airway. \u2022 Early cessation of tPA infusion is critical in the management of this complication. Recent studies and guidelines emphasize that while the angioedema associated with tPA is bradykinin-mediated, initial management with anti-histamines and steroids remains standard practice, along with vigilant airway monitoring. There is emerging interest in specific bradykinin inhibitors (like icatibant), but these are not yet standard.",
    "exam_year": "2019",
    "exam_type": "Part I",
    "image_url": "page_18.png"
  }
]